Tobam Reduces Stock Holdings in Axon Enterprise, Inc $AXON

Tobam decreased its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 16.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,166 shares of the biotechnology company’s stock after selling 803 shares during the period. Tobam’s holdings in Axon Enterprise were worth $3,449,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. TCI Wealth Advisors Inc. bought a new position in shares of Axon Enterprise during the 2nd quarter valued at about $214,000. Duncker Streett & Co. Inc. boosted its stake in Axon Enterprise by 3.2% during the second quarter. Duncker Streett & Co. Inc. now owns 14,501 shares of the biotechnology company’s stock valued at $12,006,000 after buying an additional 448 shares during the last quarter. EFG Asset Management North America Corp. grew its holdings in Axon Enterprise by 17.8% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,701 shares of the biotechnology company’s stock valued at $10,511,000 after buying an additional 1,918 shares in the last quarter. New York Life Investment Management LLC increased its stake in Axon Enterprise by 3.2% in the 2nd quarter. New York Life Investment Management LLC now owns 11,044 shares of the biotechnology company’s stock worth $9,144,000 after acquiring an additional 341 shares during the last quarter. Finally, Sivia Capital Partners LLC purchased a new stake in shares of Axon Enterprise during the 2nd quarter worth approximately $284,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Stock Down 2.1%

Shares of AXON stock opened at $572.18 on Wednesday. The stock’s 50-day simple moving average is $712.93 and its 200-day simple moving average is $736.90. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The firm has a market capitalization of $45.15 billion, a PE ratio of 141.28, a P/E/G ratio of 29.49 and a beta of 1.45. Axon Enterprise, Inc has a fifty-two week low of $469.24 and a fifty-two week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business had revenue of $710.64 million during the quarter, compared to analysts’ expectations of $704.83 million. During the same period in the previous year, the company posted $1.45 earnings per share. Axon Enterprise’s revenue for the quarter was up 30.6% compared to the same quarter last year. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on AXON. Piper Sandler decreased their price target on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Axon Enterprise in a report on Wednesday, October 8th. Bank of America increased their target price on Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Craig Hallum raised shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 target price on the stock in a research report on Tuesday, August 5th. Finally, Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 2nd. Fourteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $810.71.

Insider Buying and Selling

In related news, CFO Brittany Bagley sold 5,000 shares of the firm’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $713.88, for a total value of $3,569,400.00. Following the transaction, the chief financial officer directly owned 93,592 shares of the company’s stock, valued at approximately $66,813,456.96. This trade represents a 5.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Joshua Isner sold 15,919 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the completion of the transaction, the president owned 238,379 shares in the company, valued at approximately $177,892,712.54. This trade represents a 6.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 49,932 shares of company stock worth $36,802,716 in the last ninety days. 4.40% of the stock is owned by corporate insiders.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.